Have a feature idea you'd love to see implemented?
Let us know!
PTGX Protagonist Therapeutics Inc
Price (delayed)
$41.65
Market cap
$2.48B
P/E Ratio
14.41
Dividend/share
N/A
EPS
$2.89
Enterprise value
$2.36B
Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2
Highlights
The equity has soared by 76% YoY
The quick ratio has contracted by 23% from the previous quarter and by 9% YoY
Key stats
What are the main financial stats of PTGX
Market
Valuations
Earnings
Shares outstanding
59.6M
Market cap
$2.48B
Enterprise value
$2.36B
Price to earnings (P/E)
14.41
Price to book (P/B)
4.61
Price to sales (P/S)
7.95
EV/EBIT
13.65
EV/EBITDA
13.4
EV/Sales
7.29
Revenue
$323.8M
EBIT
$173.08M
EBITDA
$176.27M
Free cash flow
$229.23M
Per share
Balance sheet
Liquidity
EPS
$2.89
Free cash flow per share
$3.71
Book value per share
$9.03
Revenue per share
$5.24
TBVPS
$9.78
Total assets
$603.86M
Total liabilities
$71.94M
Debt
$10.9M
Equity
$531.92M
Working capital
$432.19M
Debt to equity
0.02
Current ratio
10.7
Quick ratio
10.51
Net debt/EBITDA
-0.68
Margins
Efficiency
Dividend
EBITDA margin
54.4%
Gross margin
100%
Net margin
52.8%
Operating margin
46.1%
Return on assets
31%
Return on equity
34.7%
Return on invested capital
56%
Return on capital employed
30.9%
Return on sales
53.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTGX stock price
How has the Protagonist Therapeutics stock price performed over time
Intraday
2.46%
1 week
1.49%
1 month
-9.38%
1 year
139.92%
YTD
81.64%
QTD
-7.44%
Financial performance
How have Protagonist Therapeutics's revenue and profit performed over time
Revenue
$323.8M
Gross profit
$323.8M
Operating income
$149.11M
Net income
$170.85M
Gross margin
100%
Net margin
52.8%
PTGX's operating income has surged by 197% year-on-year but it is down by 2.1% since the previous quarter
The operating margin has contracted by 3.4% from the previous quarter
Growth
What is Protagonist Therapeutics's growth rate over time
Valuation
What is Protagonist Therapeutics stock price valuation
P/E
14.41
P/B
4.61
P/S
7.95
EV/EBIT
13.65
EV/EBITDA
13.4
EV/Sales
7.29
The equity has soared by 76% YoY
The P/B is 28% more than the 5-year quarterly average of 3.6 and 18% more than the last 4 quarters average of 3.9
The stock's price to sales (P/S) is 95% less than its 5-year quarterly average of 146.0 and 25% less than its last 4 quarters average of 10.6
Efficiency
How efficient is Protagonist Therapeutics business performance
PTGX's ROA has soared by 163% year-on-year but it is down by 12% since the previous quarter
The company's return on equity has surged by 163% YoY but it fell by 11% QoQ
The ROIC has soared by 132% YoY but it has contracted by 29% from the previous quarter
Dividends
What is PTGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTGX.
Financial health
How did Protagonist Therapeutics financials performed over time
The total liabilities has soared by 158% YoY
Protagonist Therapeutics's total assets has soared by 83% YoY
The debt is 98% smaller than the equity
The debt to equity has soared by 100% YoY
The equity has soared by 76% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.